Fusion transcriptome landscape in glioblastoma: Incidence and therapeutic implications
Approximately 9% of GBMs harbor targetable fusions, with five genes (<i>FGFR3</i>, <i>MET</i>, <i>EGFR</i>, NTRK2, <i>PDGFRA</i>) comprising 8%. These findings support multi-arm clinical trials to evaluate targeted therapies, potentially improving outcomes for molecularly defined GBM subgroups.
Authors
- Negar Sadeghipour (ORCID: https://orcid.org/0000-0002-6348-4490)
- Soma Sengupta (ORCID: https://orcid.org/0000-0003-4577-1397)
- Manmeet S. Ahluwalia (ORCID: https://orcid.org/0000-0003-3794-9511)
- Mark R. Gilbert (ORCID: https://orcid.org/0000-0003-2556-9722)
- Michael Glantz (ORCID: https://orcid.org/0000-0003-4877-5094)
- Joanne Xiu (ORCID: https://orcid.org/0000-0001-8744-5827)
- Sonikpreet Aulakh (ORCID: https://orcid.org/0000-0001-7150-5805)
- Theodore Nicolaides (ORCID: https://orcid.org/0000-0002-0637-1086)
- Shawn Kothari
Institutions
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- West Virginia University (US)
- Baptist Hospital of Miami (US)
- National Institutes of Health (US)
- West Virginia University Hospitals (US)
- Baptist Health South Florida (US)
- Northwestern University (PH)
- Caris Life Sciences (United States) (US)
- Penn State Milton S. Hershey Medical Center (US)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1093/noajnl/vdaf238
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00